Two stocks in Healthcare
Danaher vs Medtronic: profit, growth, debt and price compared
Medtronic is stronger on 4 of 7 figures: sales growth, price for its expected profit, dividend and price trend. Danaher is stronger on 3: profit margin, debt and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| DanaherDHR | MedtronicMDT | |
|---|---|---|
| Net margin | Stronger: 16.9% | 13.9% |
| Revenue growth, past year | +8.28% | Stronger: +13.73% |
| Debt to equity | Stronger: 51.8% | 55.4% |
| Forward P/E | 24.5× | Stronger: 15.7× |
| Dividend yield | 0.71% | Stronger: 2.83% |
| Analysts | Stronger: Strong buy · 21 | Buy · 26 |
| From its 200-day average | +9.3% | Stronger: +12.5% |
Share price over the past year
- Danaher+1.4%
- Medtronic−0.1%
18 Nov 202518 Nov 2026
Danaher or Medtronic: which is stronger?
- DHR
Which is more profitable?
Danaher keeps more of each sale as profit: 16.9% against 13.9%.
- MDT
Which is growing its sales faster?
Medtronic is growing its sales faster: +13.73% over the past year, against +8.28%.
- DHR
Which has borrowed less?
Danaher has borrowed less: its debt is 51.8% of what its shareholders own, against 55.4% for Medtronic.
- MDT
Which costs less for the profit it is expected to make?
Medtronic costs less for the profit it is expected to make: 15.7× its forward earnings, against 24.5×.
- MDT
Which pays more in dividends?
Medtronic pays more back in dividends for what a share costs: 2.83% a year, against 0.71%.
- DHR
Which do analysts rate higher?
Analysts are warmer on Danaher: Strong buy, against Buy for Medtronic.
- MDT
Which is in the stronger price trend?
Medtronic's price is in the stronger trend: 12.5% above its 200-day average, against 9.3% above.
What each company does
DHRDanaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
Reports results on 27 January 2027
MDTMedtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
Reports results on 24 November 2026
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.